Free tool · No account
Clinical trials for multiple myeloma
Multiple myeloma has a deep bench of trials, including CAR-T and bispecific antibodies. Which trials fit usually depends on how many prior treatments there have been.
568 recruiting trials. Showing a sample.
- recruitingNCT06028087
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous t...
Listed by the study for Multiple Myeloma. Record updated 2025-03-14.
Sponsored by Gruppo Italiano Malattie EMatologiche dell'AdultoFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT04603872
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Listed by the study for Multiple Myeloma in Relapse. Record updated 2020-10-28.
Sponsored by Zhejiang UniversityFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07053436
Horizon Two: HR NDMM (MMRC-100)
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an...
Listed by the study for High Risk Newly Diagnosed Multiple Myeloma. Record updated 2026-10-02.
Sponsored by Multiple Myeloma Research ConsortiumFull details on ClinicalTrials.gov → - recruitingNCT05283993
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and resp...
Listed by the study for Multiple Myeloma. Record updated 2026-09-16.
Sponsored by Peking University First HospitalFull details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT05093335
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic ...
Listed by the study for Multiple Myeloma. Record updated 2026-02-05.
Sponsored by Memorial Sloan Kettering Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04508790
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well leflunomide, pomalidomide, and dexamethasone work for the treatment of multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enz...
Listed by the study for Recurrent Plasma Cell Myeloma. Record updated 2026-05-29.
Sponsored by City of Hope Medical CenterFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06574126
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
This is an open-label, single arm, multicenter, interventional study with Dara-VRD followed by cilta-cel in high-risk smoldering multiple myeloma (SMM) patients. The primary objectives of this trial, related with efficafy and safety of the treatment, are i) to evaluate the pr...
Listed by the study for High Risk Smoldering Multiple Myeloma. Record updated 2024-10-26.
Sponsored by PETHEMA FoundationFull details on ClinicalTrials.gov → - recruitingNCT04234022
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical...
Listed by the study for Multiple Myeloma. Record updated 2026-04-09.
Sponsored by The Royal Wolverhampton Hospitals NHS TrustFull details on ClinicalTrials.gov → - recruitingNANCT05135351
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity a...
Listed by the study for Multiple Myeloma. Record updated 2026-07-27.
Sponsored by University of NebraskaFull details on ClinicalTrials.gov → - recruitingNCT07014865
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Individuals with multiple myeloma (MM) are vulnerable because of the effects of systemic organ damage and the side effects of treatment. A decline in patients' health-related quality of life (HRQoL) and a compromised participation in everyday life was reported. The diagnosis o...
Listed by the study for Multiple Myeloma (MM). Record updated 2025-08-29.
Sponsored by Azienda USL Reggio Emilia - IRCCSFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this multiple myeloma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.